AZN Astrazeneca PLC

38.8
+0.03  (+0%)
Previous Close 38.77
Open 38.77
Price To Book 7.89
Market Cap 101792195682
Shares 2,623,510,198
Volume 5,430,254
Short Ratio 3.07
Av. Daily Volume 5,568,590

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b/2 preliminary data due 2H 2019.
Tagrisso and Lerociclib (G1T38)
EGFR mutation-positive non-small cell lung cancer (NSCLC)
Phase 3 data due 2020.
Tezepelumab - NAVIGATOR
Asthma
Expanded approval announced August 28, 2017.
Faslodex (fulvestrant)
Monotherapy for expanded use in women with HR+, HER2- advanced breast cancer
Pooled MACE safety data 1H 2019.
Roxadustat
Anaemia in Chronic Kidney Disease
Phase 3 data due 2020.
Farxiga (Dapa-CKD)
Chronic Kidney Disease
Phase 3 data presented 18 March, 2019 noted 18% decrease in MACE events vs placebo.
Farxiga - DECLARE
Type-2 diabetes
Phase 1 trial - two patients have recorded complete responses.
MEDI0457
HPV-associated squamous cell carcinoma of the head & neck (SCCHN)
Phase 3 data released November 1, 2017 - primary endpoint not met.
Tralokinumab (STRATOS2)
Severe, uncontrolled asthma
Phase 3 data due 2020.
Farxiga (Dapa-HF)
Heart failure
Phase 3 data released May 30, 2018. Primary endpoint not met.
Benralizumab - TERRANOVA
COPD
Phase 3 data due 2020.
Roxadustat
Myelodysplastic syndromes (MDS)
Approval announced March 31, 2017.
Tagrisso
Epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC)
Phase 3 data due 2020 or later.
Durvalumab (ADJUVANT)
Adjuvant Non-small cell lung cancer (NSCLC)
Phase 3 trial did not meet primary endpoint - May 10, 2017.
Tralokinumab (STRATOS1)
Severe, uncontrolled asthma
Phase 3 trial did not meet primary endpoint - noted July 26, 2018.
Selumetinib - ASTRA
Thyroid cancer
Phase 3 data due 2H 2019.
PT010
Chronic obstructive pulmonary disease (COPD)
FDA approval announced September 13, 2018.
Moxetumomab
Cancer - leukaemia
FDA Approval announced December 19, 2018.
Lynparza - SOLO 1
First-line ovarian cancer following platinum-based chemotherapy
Approval announced August 17, 2017.
Lynparza - SOLO 2
Second-line ovarian cancer
Phase 3 data released February 17, 2016 - primary endpoint met. Late breaker at ASCO June 4, 2017 showed HR of 0.58 (42% reduction of risk of disease progression or death). Approval announced January 12, 2018.
Lynparza
Breast cancer
Phase 3 data released July 27, 2017 - primary endpoint (PFS) not met. Overall survival data also did not meet primary endpoint - November 16, 2018.
Durvalumab +/- tremelimumab (MYSTIC)
Lung cancer
Phase 3 data due 2H 2019.
Durvalumab +/- tremelimumab (NEPTUNE)
Lung cancer
Phase 3 data 1H 2019.
Durvalumab +/- tremelimumab (KESTREL)
Head & neck cancer
Phase 3 data due 2H 2019.
Durvalumab +/- tremelimumab (DANUBE)
Bladder cancer
Phase 3 data released December 7, 2018 - primary endpoints not met.
Durvalumab +/- tremelimumab (EAGLE)
Head & neck cancer
Phase 3 data released April 24, 2018 - primary endpoints not met.
Durvalumab +/- tremelimumab (ARCTIC)
Non-small cell lung cancer (NSCLC)
Approval announced February 19, 2018.
Durvalumab (PACIFIC)
Lung cancer
Phase 3 Cardiovascular Outcome trial data released September 14, 2017 - primary efficacy objective of a superior reduction in MACE missed statistical significance (p=0.061).
Bydureon
Type 2 Diabetes
Phase 3 data released February 25, 2019 met primary endpoint.
Brilinta (THEMIS)
Type 2 Diabetes
Phase 3 TULIP 1 data released August 31, 2018. Primary endpoint not met. TULIP 2 data are due estimate 1H 2019.
Anifrolumab
Lupus
Priority Review announced August 2, 2017. Approval announced October 31, 2017.
Acalabrutinib
Relapsed or Refractory Mantle Cell Lymphoma
BLA acceptance announced December 9, 2017. PDUFA under priority review. Approval announced May 1, 2017.
Urothelial carcinoma - Bladder cancer
Bladder cancer
Second CRL issued March 17, 2017. Approval announced May 18, 2018.
Lokelma (ZS-9)
Hyperkalaemia
Approval announced February 28, 2017.
Saxagliptin and dapagliflozin
Type-2 diabetes
Approval announced November 14, 2017.
Benralizumab
Severe, uncontrolled asthma
Announced discontinuation of trial due to futility - June 12, 2018.
Lanabecestat (AZD3293) - AMARANTH
Early Alzheimer's disease
Phase 3 data released December 20, 2018 met primary and secondary endpoints.
Lynparza - SOLO 3
Third-line ovarian cancer
Phase 3 data released February 26, 2019 - PFS primary endpoint met.
Lynparza
Pancreatic cancer
Phase 3 data due 2H 2019.
Imfinzi + tremelimumab (POSEIDON)
Non-small cell lung cancer (NSCLC)
Phase 3 data due 2H 2019.
Imfinzi + tremelimumab (CASPIAN)
Small cell lung cancer (SCLC)
Phase 3 data due 2020.
Lynparza - OlympiA
HER2-negative breast cancer
Phase 3 trial did not meet primary endpoint - noted May 11, 2018.
Fasenra (benralizumab) - GALATHEA
Chronic obstructive pulmonary disease (COPD)
Phase 3 data due 2H 2019.
Lynparza
Castration-Resistant Prostate Cancer
Phase 3 data due 2H 2019.
Calquence
Chronic lymphocytic leukaemia
Phase 3 data due 2H 2019.
Lynparza + Avastin- PAOLA-1
First-line ovarian cancer
Phase 1b/2 data presented at ESMO 2018. 23% PR/CR.
Durvalumab Plus Danvatirsen
Refractory head and neck cancer
Phase 3 final OS data due 2H 2019.
Tagrisso - FLAURA
Non-small cell lung cancer (NSCLC)
Phase 3 data due 2020.
Brilinta (THALES)
Acute ischaemic stroke
Phase 3 data due 2020.
Epanova
Hypertriglyceridaemia CVOT
Phase 3 data due 2019.
Fasenra
Nasal polyps
Phase 3 data due 2020.
Imfinzi
Neoadjuvant NSCLC
Phase 2 trial met primary endpoint - noted April 4, 2019.
Fasenra
Hypereosinophilic Syndrome

Latest News

  1. AVEO Pharmaceuticals Down More Than 40% in 90 Days: Here's Why
  2. Top Ranked Income Stocks to Buy for April 17th
  3. Clovis Stalls Mid-Stage Rubraca Study for Bladder Cancer
  4. AstraZeneca’s Oncology Portfolio: Growth Trends in 2019
  5. London's FTSE 100 tugged down by miners; IWG lifts midcaps
  6. PFE or AZN: Comparing Their Earnings Growth in 2019
  7. What Are Analysts Recommending for PFE and AZN?
  8. Pharma Stock Roundup: AZN, MRK, GSK Get Regulatory Approvals, Sandoz Inks New Deal
  9. Dow 30 Stock Roundup: Procter & Gamble Hikes Dividend, Boeing Q1 Commercial Deliveries Fall
  10. Here's what to expect from the stock market next month
  11. Is AstraZeneca Stock Worth Buying Before Earnings?
  12. Alkermes Reports Positive Data From Schizophrenia Study
  13. J&J (JNJ) to Kick-start Pharma Q1 Earnings: What's in Store?
  14. AstraZeneca/Merck's Lynparza Wins EU Nod for Breast Cancer
  15. PhaseBio Stock Up on Breakthrough Therapy Status for PB2452
  16. Inovio Earns 3rd Milestone Fee From AstraZeneca for MEDI0457
  17. The Zacks Analyst Blog Highlights: Pfizer, Teva, Novartis, Merck and AstraZeneca
  18. Is AstraZeneca PLC's (LON:AZN) Balance Sheet A Threat To Its Future?
  19. City of London alarmed at EU’s no-deal Brexit equity trading plan
  20. Pfizer's Ibrance Gets FDA Approval for Breast Cancer in Men